WO2009016227A3 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
WO2009016227A3
WO2009016227A3 PCT/EP2008/060049 EP2008060049W WO2009016227A3 WO 2009016227 A3 WO2009016227 A3 WO 2009016227A3 EP 2008060049 W EP2008060049 W EP 2008060049W WO 2009016227 A3 WO2009016227 A3 WO 2009016227A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
ht2b receptor
compounds
hydroxytryptamine
interfering
Prior art date
Application number
PCT/EP2008/060049
Other languages
French (fr)
Other versions
WO2009016227A2 (en
Inventor
Gordon Bruton
Ian Cooper
David Hirst
Barry Sidney Orlek
Geoffrey Stemp
John Gerard Ward
Katie Sian Woodhouse
Original Assignee
Glaxo Group Ltd
Gordon Bruton
Ian Cooper
David Hirst
Barry Sidney Orlek
Geoffrey Stemp
John Gerard Ward
Katie Sian Woodhouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Gordon Bruton, Ian Cooper, David Hirst, Barry Sidney Orlek, Geoffrey Stemp, John Gerard Ward, Katie Sian Woodhouse filed Critical Glaxo Group Ltd
Publication of WO2009016227A2 publication Critical patent/WO2009016227A2/en
Publication of WO2009016227A3 publication Critical patent/WO2009016227A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel indoline derivatives which bind to the 5-HT2B receptor and are capable of interfering with the effects of 5-hydroxytryptamine (5-HT) at the 5-HT2B receptor; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy.
PCT/EP2008/060049 2007-08-02 2008-07-31 Novel compounds WO2009016227A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715047.7A GB0715047D0 (en) 2007-08-02 2007-08-02 Novel Compounds
GB0715047.7 2007-08-02

Publications (2)

Publication Number Publication Date
WO2009016227A2 WO2009016227A2 (en) 2009-02-05
WO2009016227A3 true WO2009016227A3 (en) 2009-04-02

Family

ID=38529161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/060049 WO2009016227A2 (en) 2007-08-02 2008-07-31 Novel compounds

Country Status (2)

Country Link
GB (1) GB0715047D0 (en)
WO (1) WO2009016227A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842794B2 (en) 2014-02-07 2020-11-24 Támogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
EP3104847B8 (en) 2014-02-07 2020-12-30 Támogatott Kutatócsoportok Irodája Novel use of sigma-1 receptor agonist compounds
DK3609486T3 (en) * 2017-04-11 2021-08-16 Ceva Sante Animale SARPOGRELATE FOR USE IN A METHOD FOR THE TREATMENT OF HEALTH DISEASE IN MAMMALS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869691A (en) * 1995-05-19 1999-02-09 Eli Lilly And Company Aminoalkyl-indoles
WO2000012475A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
WO2006038006A2 (en) * 2004-10-07 2006-04-13 Glaxo Group Limited 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869691A (en) * 1995-05-19 1999-02-09 Eli Lilly And Company Aminoalkyl-indoles
WO2000012475A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
WO2006038006A2 (en) * 2004-10-07 2006-04-13 Glaxo Group Limited 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders

Also Published As

Publication number Publication date
WO2009016227A2 (en) 2009-02-05
GB0715047D0 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
BRPI0915084B8 (en) compound, and, pharmaceutical composition
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2009023844A3 (en) 3' substituted compounds having 5-ht6 receptor affinity
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
CL2007002859A1 (en) PIRAZOL DERIVATIVE COMPOUNDS, 5-HT2A RECEIVER MODULATORS; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND USE OF THE COMPOUND FOR THE TREATMENT OF CORONARY ARTERIOPATIA, INFARTO MIOCARDICO, ANGINA, SOUND DISORDER, ASTHMA, REDUCE
UA98804C2 (en) Catecholamine derivatives and pharmaceutical composition based thereon
PL1877364T3 (en) Phenylacetylene derivatives having mglur5 receptor affinity
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2009145996A3 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
WO2008005908A3 (en) Pyridoimidazole derivatives
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2010049449A3 (en) Novel salts of sunitinib
GB0611907D0 (en) Compounds
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
EA200970849A1 (en) TRICYCLIC DERIVATIVES OF ISOHINOLINE FOR THE TREATMENT OF OBESITY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08786674

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08786674

Country of ref document: EP

Kind code of ref document: A2